Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

ImmuCell Corporation (ICCC)

NCM · Biotechnology

$11.24+0.11 (+0.99%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$101.7M
P/E (TTM)
EPS
$-0.07
Div Yield
52W Range
$4.52–$12.10
Beta
0.57

Company overview

Next earnings: 2026-08-13(16d)

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

Peers in Biotechnology

All in industry →

Recent press releases

ImmuCell Corporation has not issued a press release in this window.

SEC filings

All filings →

ImmuCell Corporation has not filed an SEC document in this window.

ImmuCell Corporation has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
88,470 sh● NEW
39,633 sh-54.5%
302,996 sh-1.8%
124,716 sh+18.6%
39,393 sh+83.5%
35,000 sh-42.6%
54,281 sh-12.9%

People at ImmuCell Corporation

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$8.1M
NI $1.4M
06/25
$6.4M
NI $501.9K
09/25
$5.5M
NI -$139.7K
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.02
Prior: $0.06
Revenue sparkline